arvinas_logoART_lg.jpg
Arvinas to Present at Upcoming Investor Conferences
02 mai 2024 07h00 HE | Arvinas Inc.
NEW HAVEN, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
SMART IMM_LOGO NEW.png
Smart Immune treats adult acute leukemia patient at final dose level in Phase I/II ReSET-02 trial
02 mai 2024 06h00 HE | Smart Immune
Smart Immune treats adult acute leukemia patient at final dose level in Phase I/II ReSET-02 trial PARIS, France, May 2, 2024 – Smart Immune, a clinical-stage biotechnology company developing...
RM Primary Logo - Humble.png
Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024
01 mai 2024 16h05 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Giants_Logo
Giants of Cancer Care® Announces the 12th Annual Class of Inductees
01 mai 2024 09h00 HE | OncLive®
CRANBURY, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- OncLive®, the nation’s leading multimedia resource for oncology professionals and Pfizer (platinum supporter), Exelixis (gold supporter) and...
Tevogen Logo Notified.png
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
01 mai 2024 08h05 HE | Tevogen Bio Inc
For full year 2023, the operating expenses for Tevogen Bio Inc were $8.8 million.
ImmuneSensor_Resize.png
ImmuneSensor Therapeutics Appoints Veteran Biopharma Executive, Thomas W. Dubensky, Jr., Ph.D., as Chief Executive Officer
01 mai 2024 08h00 HE | ImmuneSensor Therapeutics
DALLAS, May 01, 2024 (GLOBE NEWSWIRE) -- ImmuneSensor Therapeutics, a clinical-stage biotherapeutics company focused on the development of best-in-class small molecule inhibitors and agonists of the...
pharmather logo.png
PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
01 mai 2024 08h00 HE | PharmaTher Holdings Ltd.
TORONTO, May 01, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo...
TessellateBio+-+logo+without+brand+promise.png
Tessellate BIO Announces Appointment of Professor Sandra Strauss to Scientific Advisory Board
01 mai 2024 04h00 HE | Tessellate Bio
AMSTERDAM and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, today announces the appointment...
IN8bioLogo.jpg
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
30 avr. 2024 06h05 HE | IN8bio, Inc
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
Straits Research Logo- p.jpg
Global Drug Infusion System Market Size Grows Steadily at a CAGR of 6.9%: Straits Research New York, United States, April 29, 2024 (GLOBE NEWSWIRE) -- A drug infusion system is a medical device that allows fluids, medicines, and therapeutic substances to be administered directly into a...